U.S. Other Utilities Stock News

NasdaqGS:ROAD
NasdaqGS:ROADConstruction

A Look At Construction Partners (ROAD) Valuation After Strong Recent Share Price Momentum

Construction Partners (ROAD) has caught investor attention after its share price moved in recent trading, with recent returns over the past month and past 3 months putting its performance firmly under the spotlight. See our latest analysis for Construction Partners. That near term move sits on top of a much stronger run, with a 22.29% 1 month share price return and a 24.22% 3 month share price return feeding into a 1 year total shareholder return of 85.18%, which suggests momentum has been...
NasdaqGS:GLBE
NasdaqGS:GLBEMultiline Retail

Stronger Profitability, Higher Guidance and Buybacks Could Be A Game Changer For Global-E Online (GLBE)

In February 2026, Global-E Online Ltd. reported fourth-quarter 2025 sales of US$336.66 million and net income of US$62.45 million, issued full-year 2026 revenue guidance of US$1.21–US$1.27 billion, and confirmed completion of a US$72 million share repurchase covering 1,938,665 shares. The combination of stronger profitability, higher revenue guidance, and a completed buyback program highlights management’s confidence in Global-E Online’s financial position and growth plans. Next, we’ll...
NYSE:FUN
NYSE:FUNHospitality

Six Flags Entertainment (FUN) Is Down 6.6% After Deep 2025 Losses And Investor Exit Has The Bull Case Changed?

In February 2026, Six Flags Entertainment reported its fourth-quarter and full-year 2025 results, showing quarterly revenue of US$116.97 million and a quarterly net loss of US$92.38 million, while full-year revenue reached US$3.10 billion with a much larger full-year net loss of US$1.60 billion. The earnings release, combined with Broyhill Asset Management’s exit after citing integration challenges, weather exposure, pressure on lower-income guests, and leadership changes, has sharpened...
NYSE:ALX
NYSE:ALXRetail REITs

Assessing Alexander’s (ALX) Valuation After Vacancies Plan And Refinancing Shift Investor Outlook

Recent commentary on Alexander's (ALX) argues that its vacant retail space is part of a plan to unlock value, not lasting damage, with a refinancing improving liquidity and supporting ongoing dividend payments. See our latest analysis for Alexander's. At a share price of $234.62, Alexander's has seen a 9.86% 90 day share price return and a 7.20% year to date share price return, while the 1 year total shareholder return sits at 18.67%, which reflects recent performance across different time...
NYSE:CTRI
NYSE:CTRIConstruction

How Investors Are Reacting To Centuri Holdings (CTRI) Record Backlog And 2026 Revenue Guidance

In February 2026, Centuri Holdings reported fourth-quarter 2025 results showing revenue of US$858.6 million and net income of US$30.18 million, contributing to full-year revenue of US$2.98 billion and net income of US$22.4 million, alongside issuing 2026 revenue guidance of US$3.24 billion to US$3.54 billion. Management also highlighted a backlog of about US$5.9 billion and a roughly US$13 billion bidding pipeline, indicating substantial contracted and potential work already identified for...
NYSE:GXO
NYSE:GXOLogistics

GXO Wins Hunkemöller’s First Outsourced B2B Logistics Deal Might Change The Case For Investing In GXO (GXO)

GXO Logistics, Inc. announced that it successfully launched a multi-year partnership with lingerie retailer Hunkemöller, taking over its B2B logistics operations in Almere from January 1, 2026, using a 32,000-square-meter, highly automated site to support pan-European distribution. This is Hunkemöller’s first move to outsource B2B logistics, underscoring GXO’s role as a technology-led logistics partner integrating robotics and shuttle systems into a single, large-scale European hub. Next,...
NasdaqGS:PCRX
NasdaqGS:PCRXPharmaceuticals

Pacira BioSciences (PCRX) Valuation Check After Mixed Share Performance And High P/E Multiple

Why Pacira BioSciences is on investors’ radar today Pacira BioSciences (PCRX) has been drawing attention after a mixed share price pattern, with a 6.7% gain over the past month contrasting with negative returns over the past 3 months and year to date. See our latest analysis for Pacira BioSciences. At the current share price of $21.91, Pacira BioSciences shows a mixed picture, with a 6.7% 30 day share price return set against a 10.4% year to date share price decline and a 68.3% five year...
NasdaqGS:INTR
NasdaqGS:INTRBanks

Assessing Inter & Co (NasdaqGS:INTR) Valuation After Strong Multi‑Year Shareholder Returns

With no fresh headline driving Inter & Co (NasdaqGS:INTR) today, recent performance and fundamentals come into focus as investors weigh its returns profile against revenue of R$5,984.585 and net income of R$1,312.39. See our latest analysis for Inter & Co. Inter & Co’s share price has eased in the short term, with a 7 day share price return of 5.84% and 30 day share price return of 6.65%, yet its 1 year total shareholder return of 64.56% and 3 year total shareholder return of almost 4x...
NYSE:GHC
NYSE:GHCConsumer Services

How Graham Holdings’ (GHC) Steady Dividend Amid Sharply Lower Earnings May Reshape Its Investment Case

Graham Holdings Company recently reported past fourth-quarter and full-year 2025 results showing slightly higher sales but much lower net income and earnings per share, alongside US$10,100,000 of impairment charges, compared with higher impairments and far higher profit a year earlier. Despite the profit drop, the company affirmed a regular quarterly dividend of US$1.88 per share and highlighted operational progress in education and healthcare businesses. We’ll now look at how the sharp...
NasdaqGS:ASTE
NasdaqGS:ASTEMachinery

A Look At Astec Industries (ASTE) Valuation After Its Recent Strong Share Price Momentum

Astec Industries stock: recent performance in focus Astec Industries (ASTE) has drawn interest after a strong run, with total return figures of 27% over the past month and 42% over the past 3 months. This has put recent price action front and center for investors. See our latest analysis for Astec Industries. The latest share price of US$62.09 sits alongside a 30 day share price return of 27.44% and a 1 year total shareholder return of 76.73%. This signals strong recent momentum following a...
NasdaqGS:HLIT
NasdaqGS:HLITCommunications

How New Operator Integrations At Harmonic (HLIT) Have Changed Its Investment Story

In February 2026, Harmonic announced new wins and integrations, including Alcom adopting its XOS Advanced Media Processor for Nordic white-label video services, a joint integration with ATX Networks to simplify DOCSIS 4.0 upgrades, and izzi using Harmonic’s cOS virtualized broadband platform to support a large fiber rollout in Mexico. Together, these developments show Harmonic’s technology becoming more deeply embedded in operators’ core broadband and video infrastructures, potentially...
NYSE:CON
NYSE:CONHealthcare

Earnings Beat, Dividend Hike, and Buybacks Might Change The Case For Investing In Concentra (CON)

Concentra Group Holdings Parent, Inc. recently reported its fourth-quarter and full-year 2025 results, with Q4 revenue rising to US$539.08 million and net income to US$34.69 million, while also declaring a US$0.0625 per-share cash dividend payable in March 2026. Management is pairing this earnings momentum with expansion plans focused on smaller, bolt-on acquisitions and a stepped-up de novo clinic pipeline, supported by a new US$100.00 million share repurchase program. We’ll now examine how...
NYSE:UPS
NYSE:UPSLogistics

UPS Network Overhaul Weighs On Costs Valuation And Dividend Coverage

UPS (NYSE:UPS) is accelerating its "Network of the Future" overhaul, which includes closing up to 200 manual package sorting facilities by 2030. The company plans to shift more volume into highly automated hubs as part of a broad redesign of its U.S. operations. UPS is offering employee buyouts and preparing for large-scale workforce reductions as it reconfigures its network. UPS sits at the center of global e‑commerce and business shipping, and its network decisions can influence how...
NYSE:CNH
NYSE:CNHMachinery

Why CNH Industrial (CNH) Is Down 5.8% After Weaker Earnings and a Sharper “Iron + Tech” Pivot

In February 2026, CNH Industrial N.V. reported fourth-quarter 2025 results showing revenue rising to US$5,157 million while quarterly net income fell to US$86 million, and full-year 2025 earnings declined to US$510 million on revenue of US$18,095 million. Despite this earnings pressure, the company’s latest 10-K filing emphasized its “Iron + Tech” approach, prioritizing precision agriculture, automation, and connectivity to reshape its equipment and services model. We’ll now examine how this...
NYSE:AX
NYSE:AXBanks

Why Axos Financial (AX) Is Down 10.8% After Hot PPI Rekindles Fed Rate Cut Doubts

In late February 2026, Axos Financial, a digital-focused US bank, was caught in a broad financial sector downturn after a higher-than-expected January Producer Price Index reading reinforced concerns about persistent inflation and constrained room for near-term Federal Reserve rate cuts. This inflation surprise matters for Axos because sustained elevated rates can pressure bank net interest margins, directly affecting how profitably it turns deposits into loans and other interest-earning...
NYSE:ADC
NYSE:ADCRetail REITs

A Look At Agree Realty (ADC) Valuation After Recent Share Price Momentum And Premium P/E Multiple

Agree Realty (ADC) has drawn attention after its recent share performance, with the stock last closing at $80.48. For income focused investors, the real estate investment trust’s profile may warrant a closer look. See our latest analysis for Agree Realty. The recent 11.8% 1 month share price return, on top of an 11.6% year to date share price return, sits alongside a 5 year total shareholder return of 54.4%, suggesting momentum has been building over both shorter and longer horizons. If this...
NYSE:WD
NYSE:WDDiversified Financial

Walker & Dunlop (WD) Valuation Check As Market Views Clash On Undervaluation And Rich P/E Ratio

Why Walker & Dunlop (WD) is on investors’ radar today Walker & Dunlop (WD) has drawn investor attention after a period of weaker share performance, with the stock showing negative returns over the past year and past 3 months. This has prompted some investors to take a closer look at its fundamentals. At a last close of US$46.01, the company sits against a backdrop of mixed signals. These include a value score of 1 and recently reported annual revenue of US$1,160.01m alongside net income of...
NYSE:SSB
NYSE:SSBBanks

Why SouthState Bank (SSB) Is Down 6.4% After Inflation Jolt Hits Regional Lenders

In late February 2026, SouthState Bank was caught up in a broad financial sector pullback after hotter-than-expected U.S. producer inflation data and renewed concerns about banks’ credit quality and loan performance. The episode underscored how macroeconomic inflation surprises and shifting expectations for Federal Reserve policy can quickly alter sentiment toward regional lenders’ balance-sheet risks. Next, we’ll examine how these inflation and credit-quality concerns interact with...
NasdaqGS:MSFT
NasdaqGS:MSFTSoftware

Is It Time To Reconsider Microsoft (MSFT) After Recent AI And Cloud Growth Focus?

If you are wondering whether Microsoft is still priced attractively or if the best days are already reflected in the share price, this article walks through what the numbers indicate about its current valuation. Microsoft shares last closed at US$392.74, with returns of a 1.1% decline over 7 days, a 9.4% decline over 30 days, a 17.0% decline year to date, a 0.3% decline over 1 year, 57.5% over 3 years and 76.7% over 5 years. This gives you a broad sense of how the stock has behaved across...
NasdaqGM:ANIP
NasdaqGM:ANIPPharmaceuticals

Does Record 2025 Profitability and Reaffirmed 2026 Outlook Change The Bull Case For ANI Pharmaceuticals (ANIP)?

In late February 2026, ANI Pharmaceuticals, Inc. reported past fourth-quarter 2025 sales of US$247.06 million and net income of US$27.49 million, alongside full-year 2025 sales of US$883.37 million and a swing to profitability. The company also reaffirmed its 2026 revenue outlook of US$1.06 billion to US$1.12 billion, underpinned by strong rare disease and generics performance, including expanded uptake of Cortrophin Gel. Now we’ll examine how this record 2025 performance and reaffirmed...
NasdaqGS:PCVX
NasdaqGS:PCVXBiotechs

Vaxcyte (PCVX) Is Up 5.5% After Unveiling VAX-31 Data, Phase 3 Plans And New Financing - Has The Bull Case Changed?

In February 2026, Vaxcyte reported a full-year 2025 net loss of US$766.63 million and higher loss per share, while also raising roughly US$408.10 million through an at-the-market follow-on equity offering and filing additional shelf capacity linked to employee stock plans. Alongside these financing moves, the company highlighted unprecedented Phase 2 results for its VAX-31 pneumococcal vaccine, rapid progression into multiple Phase 3 trials, and completion of a large-scale manufacturing...
NasdaqGS:COLL
NasdaqGS:COLLPharmaceuticals

A Look At Collegium Pharmaceutical (COLL) Valuation After Mixed Q4 2025 Results And Updated 2026 Guidance

Collegium Pharmaceutical (COLL) shares came under pressure after its Q4 and full year 2025 report, where earnings and revenue missed some analyst estimates, while management reaffirmed and slightly lifted 2026 guidance. See our latest analysis for Collegium Pharmaceutical. The Q4 miss has come with a reset in expectations, with the 1 day share price return of a 5.77% decline at US$41.67 extending a 30 day share price return of a 9.26% decline, even though the 1 year total shareholder return...
NYSE:XPOF
NYSE:XPOFHospitality

Assessing Xponential Fitness (XPOF) Valuation After Weak Earnings And Lower 2026 Revenue Guidance

Xponential Fitness (XPOF) is back in focus after reporting fourth quarter and full year 2025 results, along with 2026 revenue guidance that points to a lower range than the prior year. See our latest analysis for Xponential Fitness. The earnings release and lower 2026 revenue guidance have coincided with sharp share price weakness, with a 1 day share price return of 47.08% decline and a 1 year total shareholder return of 67.75% decline. This points to fading momentum and a reassessment of...
NYSE:VMC
NYSE:VMCBasic Materials

Is Vulcan Materials (VMC) Fully Priced After Strong Multi Year Share Price Gains

If you are wondering whether Vulcan Materials is a fair deal at around US$310 per share, it helps to step back and look at what the current price actually reflects. The stock last closed at US$310.00, with returns of 1.5% over 7 days, 3.1% over 30 days, 5.9% year to date, 26.3% over 1 year, 73.4% over 3 years and 92.3% over 5 years, which may shape how investors are thinking about its potential and its risks today. Recent coverage has focused on Vulcan Materials as a key supplier of...